Skip to main content
. 2020 Feb 21;15(2):e0228064. doi: 10.1371/journal.pone.0228064

Table 1. Comparison between practice effects group and non-practice effects group.

Study Total Duration
(months)
Duration
Between baseline and
2nd measurement
(months)
N (%) with Practice Effects Baseline ADAS-cog11 Baseline Age, y Education, y
Treatment Placebo p N/
Total, (%)
PE** Non-PE p PE** Non-PE p PE** Non-PE p
ADNI
AD
24 6 NA 60/176
(34.1)
NA 60/176
(34.1)
20.0 17.9 0.0439 76.5 74.5 0.0991 14.7 14.8 0.92
DHA 18 6 76/219
(34.7)
45/151
(29.8)
0.32 121/370
(32.7)
23.5 23.7 0.8051 75.5 76.0 0.6102 14.5 14.2 0.3810
ES 15 2 34/78
(43.6)
13/38
(34.2)
0.33 47/116
(40.5)
24.2 23.6 0.7029 75.0 75.4 0.7118 12.4 12.2 0.7419
HC 18 6 99/230
(43.0)
59/160
(36.9)
0.22 158/390
(40.5)
23.8 21.4 0.0074 76.5 76.3 0.7426 14.0 13.8 0.5173
LL 18 6 74/193
(38.3)
78/188
(41.5)
0.53 152/381
(39.9)
25.5 23.1 0.0235 74.6 73.8 0.4183 14.0 14.4 0.2177
NS 14 3 83/209
(39.7)
43/103
(41.8)
0.73 126/312
(40.4)
22.9 23.9 0.3715 74.5 73.5 0.2501 14.2 13.9 0.3756
PR 16 28 weeks 32/69
(46.4)
31/69
(44.9)
0.86 63/138
(45.7)
24.1 19.9 0.0121 70.6 73.8 0.0134 14.2 13.9 0.6091
SL 24 1 103/236
(43.6)
31/76
(40.8)
0.66 134/312
(43.0)
38.3 38.9 0.5907 72.8 72.2 0.5360 12.6 12.4 0.7548
VN 26 6 26/113
(23.0)
35/114
(30.7)
0.19 61/227
(26.9)
31.2 27.4 0.0036 75.4 75.7 0.8011 13.3 13.9 0.2012
ADNI
MCI
24 6 NA 175/386
(45.3)
NA 175/386
(45.3)
12.5 10.8 0.0003 73.9 75.6 0.0241 15.5 15.8 0.45
MCI 36 3 258/457
(56.5)
145/241
(60.2)
0.35 403/698
(57.7)
11.9 10.2 <.0001 72.0 73.2 0.0240 14.7 14.7 0.996

Baseline ADAS-cog scores for participants with practice effects were significantly higher than for those without in 6 trials but were similar in the other 4 trials. Age and the years of education were mostly similar.

PE: practice effects, Non-PE: Non-practice effects